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Background: Mapping of the motor cortex by navigated transcranial magnetic stimulation (nTMS) can be used for
preoperative planning in brain tumor patients. Just recently, it has been proven to actually change outcomes by
increasing the rate of gross total resection (GTR) and by reducing the surgery-related rate of paresis significantly in cohorts
of patients suffering from different entities of intracranial lesions. Yet, we also need data that shows whether these
changes also lead to a changed clinical course, and can also be achieved specifically in high-grade glioma (HGG) patients.
Methods: We prospectively enrolled 70 patients with supratentorial motor eloquently located HGG undergoing
preoperative nTMS (2010–2014) and matched these patients with 70 HGG patients who did not undergo preoperative
nTMS (2007–2010).
Results: On average, the overall size of the craniotomy was significantly smaller for nTMS patients when compared to
the non-nTMS group (nTMS: 25.3 ± 9.7 cm2; non-nTMS: 30.8 ± 13.2 cm2; p = 0.0058). Furthermore, residual tumor tissue
(nTMS: 34.3%; non-nTMS: 54.3%; p = 0.0172) and unexpected tumor residuals (nTMS: 15.7%; non-nTMS: 32.9%; p = 0.0180)
were less frequent in nTMS patients. Regarding the further clinical course, median inpatient stay was 12 days for the
nTMS and 14 days for the non-nTMS group (nTMS: CI 10.5 – 13.5 days; non-nTMS: CI 11.6 – 16.4 days; p = 0.0446).
60.0% of patients of the nTMS group and 54.3% of patients of the non-nTMS group were eligible for postoperative
chemotherapy (OR 1.2630, CI 0.6458 – 2.4710, p = 0.4945), while 67.1% of nTMS patients and 48.6% of non-nTMS
patients received radiotherapy (OR 2.1640, CI 1.0910 – 4.2910, p = 0.0261). Moreover, 3, 6, and 9 months survival
was significantly better in the nTMS group (p = 0.0298, p = 0.0015, and p = 0.0167).
Conclusions: With the limitations of this study in mind, our data show that HGG patients might benefit from
preoperative nTMS mapping.
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Many studies have now shown that surgical neuro-oncology
requires an optimal extent of resection (EOR) since it dir-
ectly correlates with survival of glioma patients. Thus, gross
total resection (GTR) has to be the surgical aim for neuro-
surgeons when treating glioma patients [1-3]. Especially* Correspondence: Sandro.Krieg@lrz.tum.de
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unless otherwise stated.when affecting or neighboring the motor cortex, GTR is
still a neurosurgical quest requiring a multimodal ap-
proach of preoperative mapping and intraoperative map-
ping and monitoring. Intraoperatively, we already have
well-established techniques to monitor functional integrity
of the motor strip and corticospinal tract (CST) such as
continuous motor evoked potential (MEP) monitoring as
well as cortical (DCS) and subcortical electrical stimulation
[4-6]. Besides functional magnetic resonance imaging
(fMRI) and magnetoencephalography (MEG) we now have
another modality at hand for preoperative mapping: navi-
gated transcranial magnetic brain stimulation (nTMS).his is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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etrates the skull and induces an electric field within the
motor cortex, which then causes neuronal depolarization
and therefore an action potential that can be measured as
a MEP [7]. By combining the TMS technique with a neuro-
navigation unit, we are now able to navigate the TMS coil
and thus its site of cortical stimulation [8]. In this context,
nTMS was repeatedly shown to correlate well with intra-
operative DCS and already demonstrated to be superior to
fMRI and MEG [9-11]. But more importantly, nTMS has
been proven to not only influence surgical indication and
planning but also lead to an increased rate of GTR and to
a reduced rate of surgery-related paresis [12,13]. However,
this was shown in a comparatively inhomogeneous cohort
suffering from different kinds of brain lesions and without
taking into account the further clinical course [12,13].
Thus, further investigation in a more homogeneous patient
cohort including analysis of the longer clinical course
seems reasonable.
This study was therefore designed to compare the clin-
ical course of patients with motor eloquently located
supratentorial high-grade gliomas (HGG) who underwent
preoperative nTMS with a historic control group of
patients who were operated on without nTMS data by
a matched pair analysis.
Methods
Patients
Indication for nTMS and intraoperative neuromonitoring
(IOM) due to topographic association between tumor and
precentral gyrus was assessed by magnetic resonance im-
aging (MRI) for all patients. Seventy consecutive patients
suffering from motor eloquently located supratentorial
HGG (16 WHO grade III and 54 WHO grade IV gliomas)Table 1 Patient data
nTM
Mean age (years) 58.0
Gender (%) Male 64.3
Female 35.7
Median preoperative Karnofsky performance status (%) 80.0
Preoperative paresis (%) None 68.6
Mild 24.3
Severe 7.1
Histology (%) WHO grade III 22.9
WHO grade IV 77.1
Mean tumor diameter (cm) 4.1 ±
Mean follow-up (months) 12.8
Detailed overview on age, gender, Karnofsky performance status (KPS), preoperativ
follow-up of the nTMS compared to the non-nTMS group. Preoperative paresis: non
grade of muscle strength ≤ 3/5.were enrolled between 2010 and 2014, received preoperative
nTMS motor mapping, and underwent craniotomy in our
department. In order to create a control group, this pro-
spectively enrolled consecutive cohort was matched with
HGG patients (14 WHO grade III and 56 WHO grade IV
gliomas) operated on from 2007 to 2010 in our department
by the same group of surgeons. A minority of the enrolled
patients was also included in a recent trial of our group [13].
Matching criteria were tumor location, preoperative par-
esis, and histology. Group characteristics and statistical
data of both groups are provided in Table 1. Each step of
data analysis was performed by investigators blinded to
the assigned group for each patient (NS, TO).
Ethical standard
The presented study is in accordance with ethical stan-
dards outlined in the Declaration of Helsinki. The study
protocol was also approved by the local institutional
review board of the TU München (registration number:
2793/10). Every patient gave written informed consent
prior to the nTMS examination.
Clinical and oncological assessment
All clinical assessment was done blinded to the nTMS
data. Each patient underwent a detailed examination
according to a standardized protocol including sensory
function, coordination, muscle strength, and cranial nerve
function. Muscle strength was assessed according to the
British Medical Research Council (BMRC) scale. The
protocol was established in 2006 as clinical routine in
our department. Postoperatively, the neurological status
was again assessed for each patient directly after
anesthesia and daily from the first postoperative day
until discharge, again at 6–8 weeks postoperatively, andS non-nTMS p-value
± 13.8 60.3 ± 14.7 0.3328
64.3 1.0000
35.7






2.7 4.2 ± 1.8 0.9328
± 10.4 17.6 ± 19.5 0.0742
e neurological status, histology, mean tumor diameter on axial slices, and mean
e = no paresis, mild = BMRC grade of muscle strength ≥ 4-/5, severe = BMRC
Krieg et al. BMC Cancer  (2015) 15:231 Page 3 of 11during follow-ups every 3–12 months depending on
WHO grade. We clearly differentiated between permanent
and temporary paresis due to surgery. Any new or aggra-
vated paresis due to surgery that did not resolve to the
preoperative status during the regular 8-week follow-up
interval was defined as a new permanent paresis. A tem-
porary paresis, however, was defined as any new or worse
surgery-related paresis, which resolved at least during the
8-week follow-up interval. Nonetheless, as a standard of
care, we perform a direct postoperative computed tomog-
raphy (CT) scan or even MRI in all glioma patients who
present with a new paresis immediately after anesthesia.
We moreover analyzed the postoperative course of all
patients including Karnofsky performance status scale
(KPS) as well as eligibility for postoperative chemother-
apy and radiotherapy. In addition, the rate of postopera-
tive infection in terms of meningitis, which was
diagnosed by lumbar puncture in case of justified clinical
suspicion, was evaluated.Magnetic resonance imaging
All MRI scans were performed before and after surgery in
all patients with a 3 Tesla MR scanner with an 8-channel
phased array head coil (Achieva 3 T, Philips Medical
Systems, The Netherlands B.V.). Our standard included
contrast-enhanced 3D gradient echo sequence, FLAIR,
and diffusion tensor imaging (DTI). The contrast-enhanced
3D gradient echo sequence dataset was transferred to the
nTMS system (eXimia 3.2 and eXimia 4.3, Nexstim Oy,
Helsinki, Finland). The day after surgery all patients under-
went another MRI scan to evaluate the EOR. The protocol
included T1 sequences with and without contrast, FLAIR,
and diffusion-weighted imaging (DWI) to search for post-
operative ischemic events. MRI scans were also performed
during regular follow-up every 3–12 months depending on
WHO grade and current oncological treatment. Since
recurrent gliomas might affect the neurological status,
all follow-up MRI scans were cautiously reviewed for
recurrent tumors since the neurological status was only
considered during progression-free survival.
The evaluation of all MRI data was performed by at least
two board certified neuroradiologists. Regarding the EOR,
the results of this evaluation were discussed in an imaging
meeting of board certified neuroradiologists and neuro-
surgeons, and a final decision was made based on the
scanning sequences described. GTR according to MRI
was assessed when there was no residual tumor tissue
identified on postoperative scans after careful comparison
to preoperative imaging. Furthermore, the rate of com-
plications (increasing edema, ischemia, bleeding, cere-
brospinal fluid circulation = CSF dysfunction) according
to MRI was evaluated for later comparison between the
nTMS and non-nTMS group.Navigated transcranial magnetic stimulation
In this study, a nTMS system (eXimia 3.2 and eXimia 4.3,
Nexstim Oy, Helsinki, Finland) consisting of a biphasic
figure-8 TMS coil with a 50 mm radius as stimulator
combined with an infrared tracking unit (Polaris Spectra,
Waterloo, Ontario, Canada) was used as outlined in earlier
reports [10,11,14]. By using a 3D gradient echo sequence
we can visualize the stimulated cortical spots and there-
fore investigate the distribution of motor function within
the human brain.
All enrolled HGG patients of the nTMS group under-
went mapping of the primary motor cortex by a stan-
dardized protocol by an experienced investigator using
110% resting motor threshold (rMT) for the upper ex-
tremity and 130% rMT for the lower extremity in 3 to
5 mm steps perpendicular to the sulci until stimulation
did not elicit any further MEP in any direction as also
published by many groups [9,11,13-16]. Each cortical
spot at which a MEP was evoked was regarded as a part of
the motor cortex of the mapped muscles and exported from
the nTMS system via DICOM standard to the intraoperative
neuronavigation system (BrainLAB AG, Feldkirchen,
Germany).
Surgical setup
Surgical technique did not vary between groups. The re-
section of all 140 HGG was supported by monopolar DCS
in order to monitor the motor system by MEPs as de-
scribed in earlier reports [12,17,18].
As a second intraoperative modality, neuronavigation
was used throughout (Vector Vision 2®, Vector Vision
Sky®, and Curve; BrainLAB AG, Feldkirchen, Germany) in
all patients. In the nTMS group, the positive nTMS points
were visualized as 3D objects by simple auto segmentation
within the neuronavigational data set (BrainLAB iPlan®
Net Cranial 3.0.1; BrainLAB AG, Feldkirchen, Germany).
Positron emission tomography (PET) was fused and inte-
grated into the data set as well. The inclusion of nTMS
data as 3D objects in the neuronavigational planning
required about 2 to 5 minutes for each case.
Additional techniques, such as intraoperative MRI or
ultrasonography, were not used during surgery, and
five-aminolevulinic acid (5-ALA) was only used infre-
quently dependent on the surgeon`s preoperative decision.
However, there was no difference in the usage frequency
of 5-ALA between the nTMS and the non-nTMS group.
Statistical analysis
Chi-square or Fisher Exact test were performed to test
the distribution of several attributes. The Mann–Whit-
ney-Wilcoxon test for multiple comparisons on ranks
for independent samples (non-parametric distribution)
and the t-test (for parametric distribution) were used for
testing of differences between 2 groups.
Krieg et al. BMC Cancer  (2015) 15:231 Page 4 of 11All results are presented as mean ± standard deviation
(SD) and as odds ratios (OR) with 95% confidence inter-
vals (CI) (GraphPad Prism 5.0c, La Jolla, CA, USA). The




All 70 consecutive HGG patients of the nTMS group
underwent preoperative mapping of the primary motor
cortex. Mean rMT of this cohort was 33.3 ± 8.2% max-
imum stimulator output. Regarding potential nTMS-
related discomfort, no patient described the stimulation as
painful or asked for reduction of stimulation intensity




Duration of surgery was 201.0 ± 57.0 min (median
198.5 min, range 81.0 – 380.0 min) for nTMS and 208.9 ±
65.5 min (median 192.0 min, range 101.0 – 401.0 min) for
non-nTMS patients (p = 0.4495).
Craniotomy size
The lateral extension of the bone flap was 4.8 ± 1.1 cm
(median 4.5 cm, range 3.0 – 9.0 cm) for nTMS and 5.0 ±
1.1 cm (median 5.0 cm, range 2.2 – 8.0 cm) for non-
nTMS patients (p = 0.2924; Figure 1A). Anterior-posterior
(AP) extent of the craniotomy was 5.2 ± 1.1 cm (median
5.0 cm, range 3.5 – 8.2 cm) for nTMS and 6.1 ± 1.9 cm
(median 5.8 cm, range 2.1 –10.6 cm) for non-nTMS pa-
tients (p = 0.0014; Figure 1B). Resulting overall size of the
craniotomy was 25.3 ± 9.7 cm2 (median 22.5 cm2, range
12.0 – 61.6 cm2) for nTMS and 30.8 ± 13.2 cm2 (median
28.0 cm2, range 4.6 – 65.7 cm2) for non-nTMS patients
(p = 0.0058; Figure 1C). According to p-values, there was a
significant difference in both the AP extent of the cra-
niotomy as well as the overall craniotomy size between
both groups.Figure 1 Size of craniotomy. Boxplot of craniotomy extension for the nTMS
and quartile-boxes for the lateral direction (A; p = 0.2924), anterior-posterior dirKarnofsky performance status scale
Median pre- and postoperative KPS were highly compar-
able in both groups without showing statistically significant
differences (Tables 1 and 2).
Motor status
Preoperative paresis
Overall, preoperative motor deficits were found at compar-
able frequency within both patient groups since being part
of the matching algorithm. Table 1 provides detailed infor-
mation about the distribution and degree of preopera-
tive motor impairment.
Overall motor outcome
Mild postoperative paresis was found in 13 patients of the
nTMS group (18.6%), whereas 18 subjects of that group
(25.7%) showed a severe degree of motor function impair-
ment. Concerning the non-nTMS group, 15 subjects
(21.4%) were suffering from mild paresis, and 18 patients
(25.7%) were diagnosed with severe paresis postoperatively.
However, there was no significant difference between the
nTMS group and non-nTMS group (p = 0.9069).
When comparing the degree of pre- and postoperative
paresis, 1 patient of the nTMS group (1.4%) improved,
whereas 15 subjects of that group (21.4%) got worse.
Regarding subjects that were not mapped by nTMS
preoperatively, 2 patients (2.9%) improved, whereas 21
patients (30.0%) were suffering from increased motor
impairment. Again, differences between both groups
were not significant (p = 0.4028).
Motor status during follow-up
During follow-up, 14 subjects of the nTMS group
(20.0%) presented with mild and 14 subjects (20.0%)
presented with severe paresis. In contrast, a number of
11 patients of the non-nTMS cohort (15.7%) were suf-
fering from mild paresis, whereas 19 subjects (27.1%)
showed a severe degree of motor impairment. Regarding
these results, statistical analysis did not show significance
(p = 0.5581).compared to the non-nTMS group with median, min-, and max-whiskers,
ection (B; p = 0.0014) and overall size of the craniotomy (C; p = 0.0058).
Table 2 Postoperative course
nTMS non-nTMS p-value
Median postoperative Karnofsky performance status (%) 80.0 (95% CI 76.1 – 83.9) 80.0 (95% CI 76.1 – 83.9) 0.3311
Median inpatient stay (days) 12.0 (95% CI 10.5 – 13.5) 14.0 (95% CI 11.6 – 16.4) 0.0446
Residual tumor (%) 34.3 54.3 0.0172
Unexpected residual (%) 15.7 32.9 0.0180
Surgery-related paresis (%) None 78.6 70.0 0.1138
Transient 8.6 4.3
Permanent 12.9 25.7
Surgery-related complications on MRI (%) Increasing edema 6.7 5.4 0.5154
Ischemia 18.7 9.5
Bleeding 13.3 17.6
CSF circulation dysfunction 1.3 2.7
This table provides information about the postoperative course of the nTMS compared to the non-nTMS group, including Karnofsky performance status (KPS),
inpatient stay, residual tumor, unexpected residual, surgery-related paresis, and surgery-related complications as shown by MRI.
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come with motor status during follow-up, 8 patients of the
nTMS group (11.4%) improved, while motor function of 2
nTMS patients got worse (2.9%). In the group of non-
nTMS patients, 5 subjects (7.1%) increased in motor func-
tion, while 4 patients (5.7%) were suffering from increasing
paresis. Again, the difference between groups failed to
be significant (p = 0.5048).
Furthermore, permanent surgery-related paresis was
found more frequently in subjects of the non-nTMS co-
hort, while transient motor deficits occurred more often
in nTMS patients (Table 2, Figure 2). Although the results
show a clear trend, the difference in surgery-related
paresis between groups eventually did not reach statis-
tical significance (Table 2).
With regard to the clinical course between preopera-
tive status and follow-up, 3 nTMS patients (4.3%) im-
proved in motor function, while 11 subjects (15.7%)Figure 2 Surgery-related paresis on long-term follow-up. The graph ill
the percentage of patients who were diagnosed with a new permanent pa
non-nTMS group (p = 0.1113).deteriorated. Within the group of non-nTMS patients,
motor function increased in 4 subjects (5.7%) and de-
creased in 22 subjects (31.4%; Figure 3).
Peri- and postoperative complications on MRI
There was no significant difference in the distribution of
peri- and postoperative complications between both
groups (Table 2).
Postoperative infection
Within the nTMS group, postoperative infection was
observed in 6 patients (8.6%), whereas it occurred in 9
subjects of the non-nTMS cohort (12.9%, p = 0.4124).
Extent of resection and persisting surgery-related deficit
Both residual tumor tissue and unexpected residual tumor
were found significantly more frequently on postoperativeustrates the percentage of patients suffering from a transient paresis to
resis on long-term follow-up for the nTMS group in comparison to the
Figure 3 Permanent surgery-related deficit depending on preoperative paresis. The bar chart compares the percentage of patients with
and without a preoperative paresis in both the nTMS (A; p = 0.0239) and the non-nTMS group (B; p = 0.0015), which can be improved, unchanged,
or deteriorated on long-term follow-up compared to the preoperative state.
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patients (Tables 2 and 3).Inpatient stay
In total, patients of the nTMS group showed a significantly
shorter inpatient stay than patients of the non-nTMS
cohort (Table 2; Figure 4).Adjuvant therapy
Chemotherapy
Overall, there was no statistically significant difference
in the application of postoperative chemotherapy in both
groups (Table 4).
Within the nTMS group, 42 patients (60.0%) were
treated by adjuvant chemotherapy, which consisted of tem-
ozolomide (36 cases, 51.4% of patients), temozolomide +
bevacizumab (4 cases, 5.7%), temozolomide + CCNU
(1 case, 1.4%), or bevacizumab + CCNU + procarbazine
(1 case, 1.4%). Concerning patients of the non-nTMS
group, 38 (54.3%) received adjuvant chemotherapy.
Therefore, temozolomide (30 cases, 42.9% of patients),
temozolomide + bevacizumab (5 cases, 7.1%), temozolo-
mide + CCNU (1 case, 1.4%), temozolomide + capecitabin
(1 case, 1.4%), or temozolomide + ACNU (1 case, 1.4%)
were applied.Table 3 Extent of resection and surgery-related new
permanent paresis
GTR STR
nTMS non-nTMS nTMS non-nTMS
New permanent paresis (%) 17.4 28.1 12.5 34.2
No new permanent paresis (%) 82.6 71.9 87.5 65.8
p-value 0.2587 0.0570
The percentage of patients with and without new permanent paresis after gross
total resection (GTR) or subtotal resection (STR) according to postoperative MRI
for both the nTMS and non-nTMS groups.With regard to the length of adjuvant chemotherapy, pa-
tients of the nTMS group were treated 2.5 ± 2.5 months
(median 2.0 months, range 0.0 – 7.0 months), whereas sub-
jects of the non-nTMS group received treatment for 2.2 ±
2.6 months (median 1.0 month, range 0.0 – 7.0 months;
p = 0.5012).Radiotherapy
Significantly more patients underwent postoperative
radiotherapy in the nTMS group compared to the non-
nTMS cohort (Table 4).
Yet, there was no significant difference in the applied
radiation dose (nTMS: 53.6 ± 10.4 gray, median 60.0
gray, range 30.0 – 60.0 gray; non-nTMS: 57.9 ± 8.6 gray,
median 60.0 gray, range 30.0 – 70.0 gray; p = 0.1821).Time to follow-up
Table 1 provides information about mean times to follow-
up for both patient groups. According to these data,
differences between groups were not significant.Figure 4 Inpatient stay. Boxplot illustrating the duration of inpatient stay
for the nTMS group in comparison to the non-nTMS group (p = 0.0446).
Table 4 Additional therapy
nTMS non-nTMS p-value
Chemotherapy (%) WHO grade III 75.0 64.3 0.4945
WHO grade IV 55.6 51.8
Radiotherapy (%) WHO grade III 62.5 28.6 0.0261
WHO grade IV 68.5 53.6
This table gives information about the percentage of patients of the nTMS and
non-nTMS group that received adjuvant chemo- and/or radiotherapy in relation
to the WHO grade of the tumor respectively.
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In general, mean overall survival was better in the nTMS
group, but there was no significant difference between
both groups (Table 5, Figure 5). The corresponding me-
dian overall survival was 13.5 months for the nTMS and
9.1 months for the non-nTMS group.
When only taking into account mean overall survival
data of WHO grade III tumor patients, subjects of the
nTMS group survived longer than patients of the non-
nTMS cohort, and this difference was statistically signifi-
cant (Table 5). Furthermore, median overall survival was
16.7 months in the nTMS and 6.6 months in the non-
nTMS group. Yet, due to the limited number of deaths in
the WHO grade III tumor patients, these results have to be
regarded with very limited impact.
With regard to WHO grade IV tumor patients, nTMS
subjects’ mean overall survival was longer than those of
the patients of the non-nTMS group but without reach-
ing statistical significance (Table 5). In this context, the
median overall survival was 10.6 months for the nTMS
and 9.3 months for the non-nTMS cohort. Furthermore,
WHO grade IV tumor patients of the nTMS groupTable 5 Survival
All tumors Overall survival (months)
3 months survival rate (%)
6 months survival rate (%)
9 months survival rate (%)
12 months survival rate (%)
WHO grade III Overall survival (months)
3 months survival rate (%)
6 months survival rate (%)
9 months survival rate (%)
12 months survival rate (%)
WHO grade IV Overall survival (months)
3 months survival rate (%)
6 months survival rate (%)
9 months survival rate (%)
12 months survival rate (%)
Detailed survival data including mean overall survival, 3, 6, 9, and 12 months surviv
patients of both groups.showed a significantly higher survival rate after 3, 6,
and 9 months (Table 5).Discussion
In general, both groups were highly comparable in tumor
entity, size, patient age, KPS, and preoperative motor def-
icit (Table 1). Yet mean follow-up was different in both
groups due to the earlier date of surgery in the non-nTMS
group with a considerable number of survivors among the
WHO grade III patients (Table 1).Craniotomy size
According to the results of this study, there was a
statistically significant difference in the AP extent of the
craniotomy and the overall craniotomy size between both
patient cohorts (Figure 1). Therefore, it seems to be likely
that nTMS for preoperative motor mapping is able to
minimize the required size of craniotomy, probably due to
the absent necessity to perform extensive intraoperative
mapping. The surgeon’s task then is just to confirm
nTMS data by circumscribed DCS mapping, which al-
lows craniotomy sizes to be smaller especially in the AP
direction, which is usually larger to reach the rolandic
region for intraoperative DCS mapping [10]. This finding
is in accordance with a recently published study, which
showed that nTMS motor mapping can decrease the size
of craniotomy in a group of patients suffering from differ-
ent brain tumor entities [13]. However, we are not aware
of publications showing that smaller craniotomies are dir-
ectly linked to better patient outcomes or increased
safety. Thus, future studies are needed to assess whethernTMS non-nTMS p-value















al rates for all tumor patients and separately for WHO grade III and IV tumor
Figure 5 Survival. Overall survival shown via Kaplan Meier curve for both groups in WHO grade III (A; p = 0.0322), WHO grade IV (B; p = 0.3196),
and all patients (C; p = 0.1310).
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mapping can influence such parameters, too.
Residual tumor
Overall, patients of the nTMS cohort were diagnosed with
a lower rate of residual tumor tissue according to postop-
erative MRI scans in comparison to non-nTMS subjects,
which means that GTR was more often achieved in nTMS
patients (Table 2). This difference has also been observed
in two recently published studies investigating more in-
homogeneous cohorts of brain tumor patients [12,13].
Furthermore, unexpected residual was significantly more
frequently observed within the non-nTMS patients than in
their nTMS counterparts (Table 2).
Comparing these findings with current literature, Duffau
et al. [5], but also a recent meta-analysis by De Witt
Hamer et al. [19] reported an increased EOR by the use of
intraoperative mapping for low-grade [5] and infiltrative
[19] gliomas respectively, which proves the value of func-
tional mapping per se no matter whether it is performed
pre- or intraoperatively [5,19]. The relationship between
preoperative nTMS motor mapping and lower residual
tumor rates suggests that the intraoperative visualization
of nTMS mapping results on the neuronavigation system
is likely to increase the surgeons’ confidence in the neuro-
anatomy, as repeatedly reported, and therefore leads to a
more radical resection [10]. This coherence was also re-
peatedly observed in IOM investigations [5,10,20].
Surgery-related paresis
Concerning surgery-related paresis, Tables 2 and 3 show
that surgery-related permanent paresis was less frequent
in the nTMS group, especially for subtotal resection
(STR). However, it is important to state that this differ-
ence between the nTMS and non-nTMS group failed to
reach statistical significance (Tables 2 and 3). Neverthe-
less, a similar finding was also shown in two recently
published reports including patients suffering from differ-
ent entities of intracranial lesions, which both indicatedthat the rates of new postoperative motor deficits are
lower in patients undergoing nTMS motor mapping prior
to surgery [12,13].
Clinical course
Karnofsky performance status scale
Regarding the KPS, pre- and postoperative scores were
highly comparable in both groups (Tables 1 and 2),
which means that preoperative nTMS motor mapping
did not have a significant impact on postoperative KPS.
Frey et al. [12] also showed that nTMS is not likely to
change the average KPS in a significant dimension for
patients with various intraparenchymal lesions [12].
It is already known that KPS can serve as a prognostic
indicator for survival in glioma patients [21-25]. Therefore,
a positive effect of nTMS for preoperative motor mapping
on KPS would be of distinct clinical impact. However, as
indicated by the less frequent surgery-related permanent
paresis (Tables 2 and 3), nTMS still changes the postopera-
tive clinical course of HGG patients in a positive way, but
this does not seem to affect KPS scores significantly in
comparison to the non-nTMS cohort, probably due to the
relatively broad categorization of the KPS, which pri-
marily covers obvious clinical changes.
Inpatient stay
Patients of the non-nTMS group showed a significantly
longer inpatient stay than patients of the nTMS cohort
(Table 2, Figure 4). Since standard of care did not
change since 2006 in our department, this observation
could be attributed to a lower rate of surgery-related
paresis, which qualifies more patients for further treat-
ment on an outpatient basis. However, this interpret-
ation has to be confirmed by future multicenter studies
including more patients.
Adjuvant chemo- and radiotherapy
Overall, a higher rate of nTMS patients underwent adju-
vant radiotherapy treatment in comparison to subjects of
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cols did not change in the observed period, it could be
likely that this is the result of a lower surgery-related def-
icit rate among nTMS patients (Table 2). Again, further
investigations including more patients are needed to
support this explanation.
Survival
Even with the comparatively small sample size of our re-
port, 3, 6, and 9 month survival rates were significantly
better in the nTMS cohort (Table 5). This finding seems
obvious since it is the combined result of higher adju-
vant therapy rates and a higher rate of GTR in the
nTMS group (Tables 2 and 4). However, we encourage
to carefully discussing this observation in the light of
upcoming studies dealing with this issue.Further non-invasive mapping modalities
There have never been so many different mapping mo-
dalities at hand as there are today. Besides nTMS, fMRI
is a frequently used and broadly available technique for
non-invasive cortical motor mapping. Despite the fact
that resting-state as well as task-related fMRI gains in-
creasing neuroscientific importance especially for func-
tional connectivity analysis, the exact correlation between
the fMRI signal and its neurophysiological background
is still not fully understood. In that sense, fMRI only
provides an indirect measure (blood oxygenation level
dependent = BOLD-signal) of neurological activation
reflected by increased local brain metabolism but does
not measure electrophysiological function itself. How-
ever, brain metabolism regularly changes due to tumor infil-
tration, for instance [26,27]. As a consequence, fMRI – but
also PET for the same reasons – probably lacks sufficient
sensitivity and specificity to identify eloquent brain
function in the vicinity of intracerebral lesions and there-
fore, this technique should be avoided for presurgical
planning [28-31].
Another regularly used tool for motor mapping is MEG,
which, according to previous comparison studies, corre-
lates well with nTMS since its principle is also based on
neurophysiology [9,32]. But, mainly due to the high costs,
its distribution and availability are very limited despite its




Although the present study provides valuable data con-
cerning a variety of outcome factors, we have to be aware
of certain limitations of the nTMS technique itself.
The results of preoperative motor mapping by nTMS
can be confounded by different factors, such asregistration and navigation errors or imprecise determin-
ation of the individual rMT [13,14,34,35]. According to
our experience, intraoperative brain shift does not have
to be regarded as a confounder in general when fusing
nTMS data with neuronavigation, because nTMS data
is used to get an initial impression of the correlation
between function and anatomy especially directly after
opening the dura. Furthermore, the implementation of
nTMS data into neuronavigation presents its second
main value by identifying the precentral gyrus immedi-
ately after durotomy, which can then be identified visu-
ally for the remaining time of surgery.
Limitations of this particular study
The lack of randomization has to be regarded as the major
limitation of the present study. In this context, patients of
the non-nTMS group underwent surgery between 2007
and 2010, whereas the other cohort was motor-mapped
and operated on between 2010 and 2014. Yet, the used
techniques (IOM, neuronavigation) as well as the surgical
team did not change significantly from 2006 to 2014
[12,13,36].
Due to the fact that patients treated within 2013 and
2014 were also incorporated into the nTMS cohort,
mean follow-up of these subjects is comparatively low.
Therefore, the definite benefit of nTMS within these pa-
tients has probably not yet taken effect, which can de-
crease the strength of results gained among nTMS
patients.
Additionally, the control group of the present study was
not mapped for cortical motor areas by any other neuro-
imaging modality like fMRI or MEG. The practical value
of these techniques for functional mapping in brain tumor
patients due to changed anatomy and tissue metabolism
can be discussed controversially, but they represent the
more established modalities used by many centers these
days when compared to nTMS. For that reason, a system-
atic matching of the nTMS cohort to a patient group who
underwent fMRI or MEG seems reasonable. However,
since the aim of the current study was to distinctly focus
on preoperative nTMS motor mapping and its impact on
the clinical course of HGG patients, we decided to match
the nTMS group with a purely non-nTMS patient cohort.
Future impact of nTMS motor mapping on neurosurgery
The non-invasiveness and therefore presurgical applicabil-
ity of nTMS is one of its main advantages: preoperative
nTMS-based identification of motor areas was repeatedly
reported to be helpful in surgical planning for motor elo-
quent lesions, because it enables the surgeon to precisely
identify the cortical representations of individual muscles
as many surgeons are already used to during surgery
[10,14,20,37]. Additionally, thanks to nTMS mapping, we
are able to assess the risk for surgery-related paresis more
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evaluation of each patient’s individual risk of potential
surgery-related paresis, because mapping results provide
precise information about the distance between the
intended tumor resection border and the rolandic region
for every single patient on a neurophysiological basis. More
importantly, preoperative nTMS motor mapping might
further improve the outcome of brain tumor patients,
especially in terms of surgery-related paresis [12,13].Summary and significance
At least to our knowledge, this is the first study that sys-
tematically investigated the impact of preoperative nTMS-
based motor mapping on different clinical outcome param-
eters within a homogeneous cohort of HGG patients. In
this context, we were able to demonstrate that cranioto-
mies were significantly smaller in nTMS patients, and
residual tumor tissue as well as unexpected residuals
were less frequent when compared to a non-nTMS
control group. Regarding motor function, nTMS pa-
tients suffered less frequently from surgery-related par-
esis than their non-nTMS counterparts, although this
difference was not statistically significant. These find-
ings are generally in good accordance with the two re-
cently published and aforementioned studies [12,13].
Consequently, the present study revealed that the
promising results of these two publications can also be
confirmed for HGG patients. Furthermore, the present
study evaluated the further clinical course of the en-
rolled patients: median inpatient stay was shorter and
radiotherapy was also possible in a higher number of
patients in the nTMS group. Besides a trend towards
higher mean overall survival rate in the nTMS group,
there were statistically significant differences for the 3,
6, and 9 months survival in favor of the nTMS group.
Although these results are encouraging and have not
been described in the context of preoperative nTMS
motor mapping yet, we are distinctly aware of the limita-
tions of the present study, which do not allow the attribu-
tion of these findings to nTMS without any doubt of
possible confounders. Therefore, future studies including
larger patient cohorts are highly needed to explore
whether preoperative nTMS can be considered as the
distinct cause for these results.
Nonetheless, this work further increases the level of
evidence for preoperative nTMS-based motor mapping
for rolandic brain tumor patients in a group comparison
study.Conclusions
With the limitations of this study in mind, our data shows
that HGG patients might benefit from preoperative nTMSmapping with regard to various clinical outcome parame-
ters. Yet, a randomized trial should clarify the current data.
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